c75

C75 is an inhibitor synthetic fatty-acid synthase (FASN) and inhibits prostate cancer cells PC3 (IC50: 35 μM).C75 increases CPT1 activity and reduces DIO.

trans-C75 ((±)-C75) is an enantiomer of C75, which is an inhibitor of fatty-acid synthase (FASN).

SC75741 is a potent P65 inhibitor with IC50 of 200 nM

NSC756093 potentially inhibits GBP1:PIM1 interaction. NSC756093 can be used in ovarian cancer studies.

LDC7559 inhibits gasdermin D (GSDMD) by blocking neutrophil extracellular trap (NET) at late stage.

Octyl Orlistat, a potential fatty acid synthase (FASN) inhibitor, has demonstrated significant effectiveness in reducing tumor cell proliferation. By targeting FASN and inducing apoptosis, Orlistat is under investigation as an anti-tumor compound. Compared to Cerulenin and C75, Orlistat shows greater inhibitory potency in cell culture and cell lines. In LN229 cells, treatment with 200 µM Orlistat for 48 hours resulted in a 63.9 ± 8.7% reduction in cell growth, while in LT68 cells, the reduction was 76.3 ± 23.7%. Organotypic slice cultures treated with Orlistat exhibited decreased proliferation after Ki67 staining and an increase in caspase-3 cleavage.